secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001628280-25-025128
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma reports Q1 net loss $52.2M; LYL314 RMAT designation and pivotal trial on track
--------------------------------------------------------------------------------

- Net loss of $52.2M (GAAP) vs $60.7M YoY; non-GAAP net loss $46.3M vs $37.5M YoY.
- Cash, equivalents and marketable securities $330.1M as of Mar 31, 2025; sufficient into 2027.
- R&D expenses $43.4M, G&A $14.0M; workforce reduction and closure of West Hills facility impacted costs.
- LYL314 granted RMAT designation by FDA for relapsed/refractory DLBCL in third-line setting.
- Pivotal trial of LYL314 in third-line expected mid-2025; second-line pivotal trial by early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025025128/0001628280-25-025128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828025025128/lyel-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-025128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer